AEGON: 3Q in line, UK weak, all eyes on CMD in December. DEME Group: Going into 2026 with a stable order book. D'Ieteren: North America Beron peer Boyd confirms positive l/l in 3Q25, further improvement in 4Q25. KBC: 3Q above, increase in FY25 guidance across the board, first SRT is sizeable. Ontex: Peer Essity acquires Edgewell's Feminine Care activity. SBM Offshore: Progression in markets and earnings. Zabka: CVC and PG sell 100m shares via ABB
As 3Q25 turnover was € 980.9m (-9% y/y also impacted by a strong comparison base), 9M25 turnover surpassed €3bn, still a 3% y/y increase. Although y/y all segments had lower revenues in 3Q (-6% for Dredging & Intra, -12.7% for Offshore Energy, -16.3% for Environmental), DEME indicated that the YtD performance is fuelled by a double-digit YtD growth in the Offshore Energy segment which more than offset softer topline results in other segments compared to strong prior year revenues. Given this 9...
Trading update Q3 2025: another record year taking shape Highlights third quarter 2025 Group nine-month turnover surpassed 3 billion euros, a 3% increase year-over-yearOrder book is 7.5 billion euros, compared to 7.1 billion euros last yearManagement reiterates its expectations that full-year turnover will be at least in line with 2024 and forecasts a strong year-over-year EBITDA improvement, with the EBITDA margin in the range of 20% to 22%DEME took delivery of its new offshore installation vessel Norse Wind in October, completed on schedule, and set to commence operations in the first ha...
Trading update Q3 2025: een nieuw recordjaar krijgt vorm Hoogtepunten derde kwartaal 2025 De groepsomzet over negen maanden overschreed 3 miljard euro, een stijging met 3% jaar over jaarHet orderboek bedroeg 7,5 miljard euro, tegenover 7,1 miljard euro vorig jaarHet management bevestigt opnieuw zijn verwachting dat de omzet voor het volledige jaar minstens in lijn zal liggen met 2024 en verwacht een sterke verbetering van de EBITDA, met de EBITDA-marge in de range van 20% tot 22%DEME’s nieuwe offshore installatieschip Norse Wind werd volgens planning in oktober opgeleverd, en zal in de eer...
Benefitting from an almost perfect project delivery in offshore wind, especially in the US, DEME in our view should be able to improve its 2025 EBITDA to a new record level of € 881m (= 21% margin). Although its orderbook for 2026 in H1 still was screening weaker than a year ago, the early delivery and contracting of the high margin Havfram vessels (€ 900m acquisition) makes us confident that DEME also in 2026 should be able to exceed the € 800m EBITDA level. As such, we today upgrading to Outp...
The tariff war has eased, but with Trump, uncertainty has become a guarantee. While the macro-economic impact has been limited so far, the prolonged situation could still result in significant and long-lasting economic damage. We are maintaining a defensive stance in our Benelux Dynamic Top Pick List. The Federal Reserve (FED) has started its easing cycle, but the final amount of interest rate cuts is uncertain. The European Central Bank (ECB) has now largely completed its interest rate cutting ...
DEME, Aspiravi and Qair realign ownership in ScotWind project DEME announced today that an ownership realignment has taken place among the shareholders in the ScotWind project. As a result, DEME Concessions and Aspiravi International have become joint owners of the Bowdun Offshore Wind Farm. This strategic realignment is designed to streamline operations and leverage the strengths of the partners in their respective areas of expertise. Attachment
DEME, Aspiravi en Qair herschikken aandelen in ScotWind-project DEME maakt vandaag bekend dat er een herschikking van aandelen heeft plaatsgevonden onder de aandeelhouders van het ScotWind-project. Als gevolg hiervan zijn DEME Concessions en Aspiravi International gezamenlijk eigenaars geworden van Bowdun Offshore Wind Farm. Deze strategische herpositionering is bedoeld om de activiteiten te stroomlijnen en optimaal gebruik te maken van de sterktes van de partners binnen hun expertisedomeinen. Bijlage
We increased our Target Price for Biotalys to € 7.5 (was €6.1) while maintaining our Buy rating after Biotalys announced that the US EPA (Environmental Protection Agency) has issued its proposed registration decision to approve its first biofungicide, Evoca. The EPA will now initiate the final phase in its regulatory review, allowing stakeholders such as growers and industry associations 15 days to provide feedback before finalizing its regulatory decision. The EPA has also posted a final rule e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.